LP
VRDN icon

LMR Partners’s Viridian Therapeutics VRDN Stock Holding History

LMR Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Buy
+65,600
New +$1.95M ﹤0.01% 929

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LMR Partners's VRDN Position: Q1 2026 in Review

LMR Partners opened a new position in Viridian Therapeutics (VRDN) in Q1 2026: 1,159 shares worth $22.7K. The stake represents ﹤0.01% of the portfolio and ranks #1344 among its holdings. This is a return to the name: LMR Partners previously reported a position in VRDN as recently as Q4 2023.

LMR Partners first reported a position in VRDN in Q2 2019 and has held it in 13 quarters since. The position peaked at $1.46M in Q4 2022. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • LMR Partners held 1,159 shares of Viridian Therapeutics worth $22.7K as of Q1 2026.
  • Viridian Therapeutics was a new LMR Partners position in Q1 2026.
  • Viridian Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1344 holding.
  • LMR Partners first reported a position in Viridian Therapeutics in Q2 2019 and has held it in 13 quarters since.
  • LMR Partners's Viridian Therapeutics position peaked at $1.46M in Q4 2022.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.